Menu
Washingtoner
  • Home
  • Artificial Intelligence
  • Health
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Business
  • Education
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • Global Leaders Convene in Seattle to Advance Responsible AI and Cross-Border Ecosystems
  • AI Needs Guardrails Now: A New Movement Asks People Everywhere to Take the Pledge
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Spokane: City and County Issue Joint Housing and Homelessness Funding RFP
  • Spokane: Council Approves Additional Funding to Prepare for Inclement Weather
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
  • PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
  • Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
  • The Great Junk Hunt Returns to Monroe: Kick Off Your Holiday Shopping at the Ultimate Vintage Treas
  • AI Trading Agents Track Aerospace and Defense US Stocks Amid Rising Technology Investment (SATS, GILT, TSAT, IREN, JOBY, LUNR)
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • Evluma's RoadMax Edge Roadway Luminaires Earn DarkSky Approved Status
  • Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • Tacoma: Public Hearing for Off-Street Parking Code Update Set for December 1
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • Spokane: SPD Makes an Arrest in Yesterday's Early Morning Shooting
  • Spokane: Mayor Brown Introduces 2027-2028 Budget Proposal
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 307
  • Spokane: City to provide asbestos testing, host community resource meetings - 254
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 212
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 182
  • Final Week to Register for Free Spokane Community Conference - 151
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 147
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 147
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 115
  • Author Robert A. Robinson Introduces Anarchy at the AYP: - 111
  • Holiday Gambling Spending Expected to Rise 12% in December - 111

Similar on Washingtoner

  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute